BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
Study is part of strategic research collaboration between MSD and MD Anderson Cancer Center aimed to evaluate KEYTRUDA in selected GI tumors using various combinations
BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer
BL-8040 monotherapy resulted in increased infiltration of T cells into tumor. Data to be presented at the upcoming ASCO-GI conference; topline clinical results expected by H2 2018 as planned
BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA
Initiation of Phase 3 registrational study expected in second half of this year. Study to focus on stem cell mobilization for autologous transplantation in multiple myeloma patients
BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
Results to date confirm that single injection of BL-8040 mobilizes sufficient amounts of cells required for allogeneic transplantation without need for G-CSF.
BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination with Atezolizumab for Solid Tumors
Genentech has submitted all three solid tumor trials planned under its cancer immunotherapy collaboration with BioLineRx. Studies will investigate the combination in pancreatic cancer, gastric cancer and non-small cell lung cancer (NSCLC)
BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer under Immunotherapy Collaboration
Combination trial of BL-8040 and atezolizumab are part of initiative for the development of novel cancer immunotherapy combinations
BioLineRx Reports Overall Survival Results from Long-Term Follow-Up of Phase 2a Trial in r/r AML
BL-8040 in combination with high-dose Ara-C significantly improved overall survival compared to historical data
BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
Study will assess mobilization of hematopoietic stem cells by BL-8040 compared to placebo, on top of G-CSF, for autologous transplantation in multiple myeloma patients